← Back to Clinical Trials
Recruiting NCT05791162

NCT05791162 Interest of Follicular Helper Lymphocytes / Regulatory Follicular Helper Lymphocytes Ratio in IgA Nephropathy

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05791162
Status Recruiting
Phase
Sponsor Centre Hospitalier Universitaire de Besancon
Condition Glomerulonephritis, IGA
Study Type INTERVENTIONAL
Enrollment 75 participants
Start Date 2023-05-23
Primary Completion 2026-05

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Blood collectionUrine sample

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 75 participants in total. It began in 2023-05-23 with a primary completion date of 2026-05.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study aims to investigate the relevance of the Tfh/Tfr (Follicular helper T cells/ Follicular regulatory T cells) ratio in patients with IgA nephropathy: * To identify a differential expression of the Tfh/Tfr ratio in patients considered stable or progressive * To predict, at diagnosis, the clinical evolution of the disease (progressive or stable form) in the first year.

Eligibility Criteria

Inclusion Criteria: * IgA nephropathy histologically proven on renal biopsy according to KDIGO criteria, with 8 permeable glomeruli (patients diagnosed from 2009 with a minimum follow-up for their nephropathy of 5 years (arm 1) or patients diagnosed during the study (arm 2)) Control patients: Lupus or ANCA-associated vasculitis or polycystic kidney disease (arm 3) Exclusion Criteria: * Legal incapacity or limited legal capacity * Subjects with no social security coverage. * Pregnancy / No effective contraceptive method

Contact & Investigator

Central Contact

Charline Vauchy, PhD.

✉ cvauchy@chu-besancon.fr

📞 0381218875

Principal Investigator

Melchior Chabannes, MD

PRINCIPAL INVESTIGATOR

Nephrology, CHU Besançon

Frequently Asked Questions

Who can join the NCT05791162 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Glomerulonephritis, IGA. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05791162 currently recruiting?

Yes, NCT05791162 is actively recruiting participants. Contact the research team at cvauchy@chu-besancon.fr for enrollment information.

Where is the NCT05791162 trial being conducted?

This trial is being conducted at Besançon, France.

Who is sponsoring the NCT05791162 clinical trial?

NCT05791162 is sponsored by Centre Hospitalier Universitaire de Besancon. The principal investigator is Melchior Chabannes, MD at Nephrology, CHU Besançon. The trial plans to enroll 75 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology